Both in Biotechnology
Outlook Therapeutics vs Humacyte
Over the past year OTLK returned −41.0% and HUMA returned −69.2%; their daily moves had a correlation of 0.07.
OTLK −41.0% HUMA −69.2%Growth of $1, one year, split-adjusted
| Metric | OTLK | HUMA |
|---|---|---|
| Price | $0.6257 | $0.5327 |
| Market cap | $152.3M | $148.0M |
| Today | +0.74% | −2.65% |
| 1 month | −3.0% | −18.1% |
| 6 months | +211.3% | −7.3% |
| Year to date | −60.4% | −44.5% |
| 1 year | −35.5% | −69.2% |
| Revenue growth (YoY) | −99.4% | +34.9% |
| Gross margin | −95.0% | −203.2% |
| Net margin | −233554.9% | −9064.5% |
| P/E (TTM) | — | — |
| Price / sales | — | 69.8× |
| Net cash | -$7.0M | $13.7M |
| Dividend yield | — | — |
| Volatility (60d) | 116.1% | 87.0% |
| Short % of float | 38.8% | 13.0% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).